Overview

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Status:
RECRUITING

Trial end date:
2028-07-20

Target enrollment:

Participant gender:

Summary

Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Phase:

PHASE4

Details

Lead Sponsor:

Guangdong Provincial People's Hospital

Treatments:

anlotinib